BIWEEKLY COMBINATION CHEMOTHERAPY OF DOCETAXEL, IRINOTECAN AND CISPLATIN AS SECOND-LINE TREATMENT FOR ADVANCED GASTRIC CANCER

被引：0
|
作者：
Denda, T. [1 ]
Sudo, K. [1 ]
Nakamura, K. [1 ]
Hara, T. [1 ]
Yamaguchi, T. [1 ]
机构：
[1] Chiba Canc Ctr, Chiba 2608717, Japan
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：174 / 174
页数：1
相关论文
共 50 条
  • [41] A clinical study of docetaxel with or without 5′DFUR as a second-line chemotherapy for advanced gastric cancer
    Fukuto Maruta
    Satoshi Ishizone
    Manabu Hiraguri
    Yoshiro Fujimori
    Fumiaki Shimizu
    Shigeyoshi Kumeda
    Shinichi Miyagawa
    Medical Oncology, 2007, 24 : 71 - 75
  • [42] Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer
    Nakanishi, Y
    Takayama, K
    Takano, K
    Inoue, K
    Osaki, S
    Wataya, H
    Takaki, Y
    Minami, T
    Kawasaki, M
    Hara, N
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (04): : 399 - 402
  • [43] Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer
    Ridwelski, K
    Gebauer, T
    Fahlke, J
    Kröning, H
    Kettner, E
    Meyer, F
    Eichelmann, K
    Lippert, H
    ANNALS OF ONCOLOGY, 2001, 12 (01) : 47 - 51
  • [44] A phase II study of Irinotecan (Irino®) in combination with cisplatin as second line chemotherapy in patients with metastatic or locally advanced gastric cancer
    Shen, W-C
    Yang, T-S
    Chen, P-T
    Chen, J-S
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A21 - A21
  • [45] Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
    Yi, Seong Yoon
    Park, Young Suk
    Kim, Hyo Song
    Jun, Hyun Jung
    Kim, Kyoung Ha
    Chang, Myung Hee
    Park, Min Jae
    Uhm, Ji Eun
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Lee, Jong Kyun
    Lee, Kyu Taek
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (06) : 1141 - 1145
  • [46] Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
    Seong Yoon Yi
    Young Suk Park
    Hyo Song Kim
    Hyun Jung Jun
    Kyoung Ha Kim
    Myung Hee Chang
    Min Jae Park
    Ji Eun Uhm
    Jeeyun Lee
    Se Hoon Park
    Joon Oh Park
    Jong Kyun Lee
    Kyu Taek Lee
    Ho Yeong Lim
    Won Ki Kang
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 1141 - 1145
  • [47] Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
    Park, Y.
    Yi, S.
    Kim, H.
    Lee, S.
    Hwang, I.
    Park, S.
    Park, B.
    Park, J.
    Lim, H.
    Kang, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Second-Line Docetaxel plus Cisplatin for Advanced Gastric Cancer Showing Resistance to S-1
    Takagawa, R.
    Kunisaki, C.
    Makino, H.
    Nagano, Y.
    Fujii, S.
    Kimura, J.
    Kosaka, T.
    Ono, H. A.
    Akiyama, H.
    Endo, I.
    JOURNAL OF CHEMOTHERAPY, 2011, 23 (01) : 44 - 48
  • [49] CISPLATIN AND DOCETAXEL AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED GASTRIC CANCER
    Marrupe, D.
    Garcia, S.
    Lopez, E.
    Mendez, M.
    Quiben, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 112 - 113
  • [50] Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial
    Pectasides, D
    Pectasides, M
    Farmakis, D
    Kostopoulou, V
    Nikolaou, M
    Gaglia, A
    Koumpou, M
    Mylonakis, N
    Xiros, N
    Economopoulos, T
    Raptis, SA
    ANNALS OF ONCOLOGY, 2005, 16 (02) : 294 - 299
12345